Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Hodgkin Disease 7Carcinoma, Non-Small-Cell Lung 7Lymphoma 6Lung Neoplasms 6Recurrence 3Testicular Neoplasms 1Teratoma 1Pathologic Complete Response 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Mesothelioma, Malignant 1Lymphoma, Large-Cell, Anaplastic 1Kidney Neoplasms 1Glioma 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Sunitinib 14aldesleukin 10Bevacizumab 8pembrolizumab 7Nivolumab 7pazopanib 5Axitinib 5atezolizumab 4Interferon-alpha 4sintilimab 3durvalumab 3Sorafenib 3Everolimus 3Cyclophosphamide 3Chemotherapy, Adjuvant 3toripalimab 2sargramostim 2olaparib 2lenvatinib 2fludarabine phosphate 2camrelizumab 2avelumab 2Neoadjuvant Therapy 2Laparoscopy 2Ipilimumab 2Interferon alpha-2 2Immunohistochemistry 2Immune Checkpoint Inhibitors 2Gene Expression Profiling 2Fluorouracil 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Renal Cell × Vinblastine × Clear all
NCT00003181 2013-12-04

Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
35 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡